罗格列酮对2型糖尿病患者血脂及内脂素的影响

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (11): 1284-1287.

罗格列酮对2型糖尿病患者血脂及内脂素的影响

寿荣伟

杭州市萧山区第一人民医院内分泌科,杭州 311201,浙江

收稿日期:2012-11-09 修回日期:2013-06-28 出版日期:2013-11-26 发布日期:2013-11-22
作者简介:寿荣伟,男,本科,副主任医师,研究方向:内分泌常见疾病的诊治。Tel: 13758269355 E-mail: erhz@139.com

Effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus

SHOU Rong-wei

Department of Endocrinology, the First People's Hospital of Xiaoshan Distriction, Hangzhou 311201, Zhejiang, China

Received:2012-11-09 Revised:2013-06-28 Online:2013-11-26 Published:2013-11-22

摘要/Abstract

摘要： 目的: 观察罗格列酮对2型糖尿病(T2DM)患者血脂及内脂素(Visfatin)的影响,分析临床治疗效果。方法: 收集本院内分泌科2010年1月-2012年1月收治的T2DM患者84例,随机均分为对照组和罗格列酮治疗组。比较治疗前后空腹血糖(Fasting plasma glucose, FPG)、Hbalc、TC、TG、低密度脂蛋白 (Low density lipoprotein, LDL)、高密度脂蛋白(High density lipoprotein, HDL)、内脂素等生化指标变化情况。结果: 治疗前两组FPG、Hbalc、TC、TG、LDL、HDL和内脂素的表达无统计学差异(P>0.05)。治疗后两组FPG和Hbalc的表达水平均显著减低(P<0.05, P<0.01),罗格列酮组FPG和Hbalc减低幅度显著高于对照组(P<0.05)。对照组治疗前后TC、TG、LDL、HDL和内脂素的表达差异无统计学意义(P>0.05),罗格列酮组治疗后TC、TG、LDL和内脂素表达明显低于治疗前(P<0.05, P<0.01),HDL明显高于治疗前(P<0.05)。罗格列酮组临床治疗有效率(95.2%)明显高于对照组(P<0.05)。罗格列酮组不良反应发生率(23.8%)与对照组(21.4%)比较无统计学差异(P>0.05)。结论: 罗格列酮具有高效的降血糖作用,可以显著降低T2DM患者的血脂和内脂素水平,临床疗效显著,不良反应率低,建议在临床推广应用。

关键词: 2型糖尿病, 罗格列酮, 内脂素, 血脂

Abstract: AIM: To investigate the effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus (T2DM) and analysis its clinical efficacy.METHODS: A total of 84 patients with T2DM were enrolled in this study. All cases were divided into control group (n=42) and rosiglitazone treatment group (n=42). Before and after the treatment, FPG, Hbalc, TC, TG, LDL, HDL, visfatin and other biochemical indicators were compared.RESULTS: Before treatment, FPG, Hbalc, TC, TG, LDL , HDL and visfatin had no significant difference between the two groups (P>0.05). After treatment, FPG and Hbalc expression level were significantly reduce (P<0.05, P<0.01), the rosiglitazone group FPG and Hbalc reduce amplitude were significantly higher than that control group (P<0.05). Before and after treatment, treatment group TC, TG, LDL, HDL and visfatin expression difference was not statistically significant (P>0.05), the treatment group TC, TG, LDL and visfatin express were significantly lower than before treatment (P<0.05, P<0.01), HDL were significantly higher than before treatment (P<0.05). Rosiglitazone group clinical efficient (95.2%) were higher than that control group (P<0.05). The adverse reaction rates of rosiglitazone group (23.8%) and control group (21.4%) showed no significant difference (P>0.05).CONCLUSION: Rosiglitazone treatment showed more effective to reduce the serum level of glucose, lipid and visfatin, with the low rate of adverse reactions.

Key words: Type 2 diabetes mellitus, Rosiglitazone, Visfatin, Lipid

中图分类号:

R587.1

寿荣伟. 罗格列酮对2型糖尿病患者血脂及内脂素的影响[J]. 中国临床药理学与治疗学, 2013, 18(11): 1284-1287.

SHOU Rong-wei. Effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1284-1287.

参考文献

[1] Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action [J]. Diabetes Care, 2012, 35(5): 943-944.
[2] Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications [J]. Rev Diabet Stud, 2012, 9(1): 6-22.
[3] Utsunomiya K. Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance [J]. Vasc Health Risk Manag, 2012, 8(2): 429-436.
[4] 何银辉, 徐海燕, 孙霞, 等. 2型糖尿病合理用药策略[J]. 中国临床药理学与治疗学, 2011, 27(7): 837-840.
[5] 孙红, 王少明, 庄捷,等. 脂联素基因启动子-11377(C /G)基因多态性与中国2型糖尿病和罗格列酮降糖疗效的相关性研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 82-88.
[6] Abbas A, Blandon J, Rude J, et al. PPAR-γ agonist in treatment of diabetes: cardiovascular safety considerations [J]. Cardiovasc Hematol Agents Med Chem, 2012, 10(2): 124-134.
[7] 陈亚堃, 钱钧强. 罗格列酮片对2型糖尿病患者血清内脂素水平的影响[J]. 西北药学杂志, 2011, 26(4): 292-293.
[8] 邓震亭,刘芳,柴士伟,等. 罗格列酮对2型糖尿病患者血清内脂素和生长激素释放肽水平的影响[J]. 天津医药, 2012, 40(1): 28-30.
[9] Bird SR, Hawley JA. Exercise and type 2 diabetes: new prescription for an old problem [J]. Maturitas, 2012 , 72(4): 311-316.
[10] Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes[J]. Acta Diabetol, 2012, 49(4): 269- 276.
[11] Wan Y, Evans RM. Rosiglitazone activation of PPAR gamma suppresses fractalkine signaling [J]. J Mol Endocrinol, 2010, 44(2): 135-142.
[12] Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years [J]. Clin Ther, 2012, 34(10): 2082-2090.
[13] Kikuchi M, Kaku K, Odawara M, et al. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naive Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study [J]. Curr Med Res Opin, 2012, 28(6): 1007-1016
[14] 张艳芳, 杨肖红, 郑有光. 内脂素与2型糖尿病患者炎症状态及内皮功能的关系[J]. 广东医学, 2010, 31(20): 2684-2686.
[15] Gunduz FO, Yildirmak ST, Temizel M, et al. Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus [J]. Diabetes Metab J, 2011, 35(5): 523-528.